Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2015100144) CRYSTALLINE FORMS OF A MACROCYCLIC HCV NS3 INHIBITING TRIPEPTIDE
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2015/100144 International Application No.: PCT/US2014/071310
Publication Date: 02.07.2015 International Filing Date: 18.12.2014
IPC:
C07K 5/12 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
5
Peptides having up to four amino acids in a fully defined sequence; Derivatives thereof
04
containing only normal peptide links
12
Cyclic peptides
Applicants:
GILEAD SCIENCES, INC. [US/US]; 333 Lakeside Drive Foster City, California 94404, US
Inventors:
BRINGLEY, Dustin; US
CHAN, Johann; US
FUNG, Peter; US
KEATON, Katie; US
LAPINA, Olga; US
MORRISON, Henry; US
PCION, Dominika; US
Agent:
TANNER, Lorna L.; US
Priority Data:
61/920,42723.12.2013US
Title (EN) CRYSTALLINE FORMS OF A MACROCYCLIC HCV NS3 INHIBITING TRIPEPTIDE
(FR) FORMES CRISTALLINES D'UN COMPOSÉ ANTIVIRAL
Abstract:
(EN) Crystalline forms of the anti-HCV compound (1R,5S,8S,9S,10R,22aR )-5-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclopropyl]-9-ethyl-18,18-difluoro-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6] dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide (Compound I) were prepared and characterized in the solid state. Also provided are processes of manufacture and methods of using the crystalline forms.
(FR) Formes cristallines du composé anti-VHC (1aR,5S,8S,9S,10R,22aR )-5-tert-butyl-N-[(1R,2R)-2-(difluorométhyl)-1-{[(1-méthylcyclopropyl)sulfonyl]carbamoyl}cyclopropyl]-9-éthyl-18,18-difluoro-14-méthoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tétradécahydro-8H-7,10-méthanocyclopropa[18,19][1,10,3,6] dioxadiazacyclononadécino[11,12-b]quinoxaline-8-carboxamide (composé I) qui ont été préparées et qui sont caractérisées à l'état solide. L'invention concerne également des procédés de fabrication et des procédés d'utilisation desdites formes cristallines.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
UY0001035918CA2934049EP3087086JP2017503016AU2014370124ES2708993